Eloxx Pharmaceuticals raises $50m on Nasdaq

Biotech development, photo: Shutterstock
Biotech development, photo: Shutterstock

The company is developing a drug for treatment of cystic fibrosis.

Eloxx Pharmaceuticals (Nasdaq: ELOX), which develops drugs for rare genetic diseases, announced that it has raised $50 million at $9.75 per share, 8% lower than yesterday's market price. The company will be listed on Nasdaq following its financing round. Eloxx, which merged a year ago with a stock exchange shell listed on the over-the-counter index in the US, was previously controlled by former Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) chairperson Phillip Frost. Eloxx was one of Frost's few endeavors in recent years other than OPKO, to which he has devoted most of his efforts. Eloxx raised $24 million at the time of the merger in a round led by Frost. Eloxx's share price has risen 30% this year, boosting its market cap before the current round to $279 million. In August, several months after merging with the stock exchange shell, Eloxx raised $8 million from European fund LSP.

In addition to Frost, Eloxx shareholders familiar to the Israeli market includes Pontifax Venture Capital and Gilad Shabtai, one of the most prominent investors in Viber, sold three years ago for $900 million. Shabtai recently increased his stake in Eloxx to 9% in a stock exchange transaction that preceded the publication of the shelf prospectus for the current offering.

Product for treatment of cystic fibrosis

Eloxx's leading product is designed for treatment of cystic fibrosis. The company has developed technology capable of overcoming certain genetic "errors" created in the body. This approach is ostensibly suitable for a very broad range of congenital diseases resulting from a single genetic defect.

The company reported in its financial statements that it wanted to begin Phase II clinical trials of its drug for cystic fibrosis this year. It also plans to begin Phase II trials of a drug for treatment of cystinosis, which features accumulation of excess proteins in body tissue. The technology has already passed a Phase I trials for verification of its safety, and publication of the results of this trial is expected soon.

Eloxx was founded with support from Pontifax, and was managed until recently by founder and Pontifax partner Dr. Silvia Noiman. Eloxx is now managed by Robert Ward of the US, whose most recent position was CEO of Raduis Health.

According to its 2017 reports, Eloxx had $24 million in cash as of the end of 2017, after losing $21.2 million during the year.

Published by Globes [online], Israel business news - www.globes-online.com - on April 26, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

Biotech development, photo: Shutterstock
Biotech development, photo: Shutterstock
Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Traffic jam on the Ayalon Highway in Tel Aviv credit: Shutterstock Tender issued for operating Tel Aviv congestion charge

Minister of Transport Miri Regev has dropped her opposition to the project, reportedly in exchange for financing railways to Kiryat Shmona and Eilat.

Ilya Sutskever credit: Cadya Levy Ilya Sutskever's SSI raising money at $30b valuation - report

The AI startup founded last year by OpenAI founder and former chief scientist Ilya Sutskever, is in talks to raise money at a company valuation of over $30 billion, "Bloomberg" reports.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al stock still rising despite return of foreign airlines

The Israeli carrier's share price has risen 35% since the start of the year and some analysts predict further gains.

NIS 200 bills credit: Tali Bogdanovsky Reduction in cash holdings after NIS 200 bill abolishment talk

Since September 2024 there has been a dramatic decline in the number of NIS 200 bills held by the public relative to the number of NIS 100 bills, according to Bank of Israel data.

Teva CEO Richard Francis credit: Elad Malka Teva CEO responds to 25% share price fall

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

Holon employment bureau credit: Eyal Izhar Unemployment in Israel fell in January

The unemployment rate in Israel fell to 2.6% in January 2025, after seasonal adjustment, from 2.7% in December 2024, the Central Bureau of Statistics reports.

Dizengoff Center credit: Guy Hamoy Israel's economy grew 1% in 2024, above expectations

This figure reflects negative GDP per capita growth of 0.3%, because of population growth last year, the Central Bureau of Statistics reports.

Shalev Hulio and Sebastian Kutz credit: Pini Siluk and Dominic Butzmann Israeli co Dream Security raises $100m at $1.1b valuation

The company, which protects national infrastructures, was founded by former spyware company NSO Group CEO Shalev Hulio, former Austrian Chancellor Sebastian Kurz and Gil Dolev.

CyberArk CEO Matt Cohen and founder and executive chairman  Ehud Mokady  credit: PR $20b CyberArk becomes Israel's second most valuable co

The cybersecurity company's share price has almost tripled in value in the past three years.

Israel Tax Authority Head Shay Aharonovich credit: Yossi Zamir Israel Tax Authority set to publish voluntary disclosure plan

The latest procedure, delayed for over a year, will not include an anonymous track but will have a fast track for unreported cryptocurrency assets.

Tel Aviv credit: Shutterstock Meitav sees Israel housing prices falling

More Israeli households are expected to prefer renting a home rather than buying their own apartment and the consequences will be negative, Meitav investment house chief economist Alex Zabezhinsky predicts.

Sasha Troufanov credit: IDF Spokesperson Amazon CEO welcomes release of employee Sasha Troufanov

Andy Jassy said that Amazon has not commented publicly on the hostages for fear that it would negatively impact their ability to be released, or how they were treated in captivity.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018